# A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

> **NCT07391241** · PHASE2 · RECRUITING · sponsor: **Initiator Pharma** · enrollment: 24 (estimated)

## Conditions studied

- Vulvodynia

## Interventions

- **DRUG:** Pudafensine

## Key facts

- **NCT ID:** NCT07391241
- **Lead sponsor:** Initiator Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-17
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391241, "A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07391241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*